The human oral and gut microbiota plays a crucial role in various bodily functions and health conditions, including cardiovascular disease (CVD). Factors like diet, aging, lifestyle, and medications, particularly proton pump inhibitors (PPIs), can disrupt this microbiota, leading to dysbiosis.
We observed that proton pump inhibitors use in human 300OB cohort correlates with increased microbial diversity and oral-originating bacteria in the gut, alongside cardiovascular disease risk factors. However, omeprazole, a common proton pump inhibitor, induces gut dysbiosis without affecting atherosclerosis development in mice. Additionally, different synthetic diets affect gut and oral microbiota composition, among high-fat diets exacerbates obesity and metabolic disorders.
Microbiota-derived metabolites such as short-chain fatty acids (SCFAs) and bile acids (BAs) are implicated in metabolic health, with BAs showing stronger correlations with metabolic parameters. Ailine Lopez Manosalva’s thesis emphasizes the need for further research to understand the mechanisms linking dysbiosis, microbiota-derived metabolites, and CVD risk factors, considering diverse factors in microbiota management for precision medicine. Despite limitations, the study provides valuable insights into the complex interplay influencing cardio-metabolic health.
